Key Points
- Liquidia director Stephen Bloch sold 318,893 shares on Monday at an average price of $50.23, totaling about $16.0 million. After the sale, he still held 1.87 million shares, and the trade reduced his position by 14.57%.
- The company reported strong first-quarter results, with EPS of $0.52 beating estimates by $0.11 and revenue of $132.87 million topping forecasts. Revenue also surged 4,187% year over year, highlighting rapid growth.
- Analysts have turned more bullish on LQDA, with recent price-target increases from firms including HC Wainwright and Needham. The stock now carries a consensus rating of “Moderate Buy” with an average target price of $49.33.
Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Stephen Bloch sold 318,893 shares of the company's stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the completion of the transaction, the director owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. This trade represents a 14.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Liquidia Stock Up 1.7%
Shares of LQDA opened at $57.59 on Thursday. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $57.80. The firm has a market cap of $5.12 billion, a P/E ratio of 411.39 and a beta of 0.41. The firm's 50-day simple moving average is $38.70 and its 200 day simple moving average is $35.54. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.84 and a current ratio of 2.22.
Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company's revenue was up 4187.1% on a year-over-year basis. On average, analysts forecast that Liquidia Corporation will post 2.14 earnings per share for the current year.
Wall Street Analyst Weigh In
LQDA has been the subject of several recent analyst reports. HC Wainwright increased their price objective on shares of Liquidia from $55.00 to $67.00 and gave the stock a "buy" rating in a research report on Tuesday. Needham & Company LLC increased their price objective on shares of Liquidia from $54.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday. Zacks Research upgraded shares of Liquidia from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 5th. Raymond James Financial restated a "strong-buy" rating on shares of Liquidia in a report on Thursday, March 5th. Finally, Oppenheimer raised their price target on shares of Liquidia from $16.00 to $19.00 and gave the stock an "underperform" rating in a report on Thursday, March 12th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Liquidia presently has an average rating of "Moderate Buy" and a consensus target price of $49.33.
Get Our Latest Analysis on LQDA
Key Stories Impacting Liquidia
Here are the key news stories impacting Liquidia this week:
- Positive Sentiment: Liquidia reported first-quarter results that beat expectations on both earnings and revenue, reinforcing the view that commercialization is gaining traction and that profitability is improving. Liquidia Corporation Reports First Quarter 2026 Financial Results
- Positive Sentiment: Management said YUTREPIA net product sales rose 44% sequentially and projected at least $1 billion in net revenue by 2027, which signals a long growth runway if launch momentum continues. Article on YUTREPIA sales and 2027 revenue target
- Positive Sentiment: Several analysts turned more constructive after the earnings report, including Needham, BTIG, and Wells Fargo, with higher price targets and buy ratings helping support the stock. Needham price target raise
- Positive Sentiment: Liquidia was also added to Zacks’ Rank #1 “Strong Buy” list, adding to the bullish momentum around the shares. Zacks Strong Buy list
- Neutral Sentiment: CEO Roger Jeffs and Director Stephen M. Bloch both disclosed insider stock sales, but the CEO’s sale was under a pre-arranged 10b5-1 plan and the transactions are being viewed more as monitoring points than as clear operating red flags. SEC filing
- Negative Sentiment: One research note argued that YUTREPIA’s launch upside may be approaching a ceiling, suggesting some investors may worry the current growth rate becomes harder to sustain. Rating downgrade article
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in LQDA. Farallon Capital Management LLC lifted its position in shares of Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company's stock valued at $194,783,000 after purchasing an additional 4,326,876 shares in the last quarter. TCG Crossover Management LLC bought a new stake in Liquidia in the third quarter worth about $38,887,000. Caprock Group LLC bought a new stake in Liquidia in the third quarter worth about $37,114,000. MPM Bioimpact LLC raised its position in Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company's stock worth $48,316,000 after acquiring an additional 1,200,869 shares during the period. Finally, Voloridge Investment Management LLC bought a new stake in Liquidia in the third quarter worth about $12,571,000. 64.54% of the stock is owned by institutional investors.
Liquidia Company Profile
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
